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Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis
Factor Inhibitors in Patients With Rheumatoid Arthritis With and
Without Diabetes Mellitus: A Multidatabase Cohort Study
Eun Ha Kang, MD, PhD, MPH; Yinzhu Jin, MS, MPH; Gregory Brill, MS; Jennifer Lewey, MD, MPH; Elisabetta Patorno, MD, DrPH;
Rishi J. Desai, PhD; Seoyoung C. Kim, MD, ScD, MSCE
Background-—We examined the cardiovascular risk of abatacept compared with tumor necrosis factor (TNF) inhibitors in patients
with rheumatoid arthritis with and without diabetes mellitus (DM).
Methods and Results-—We conducted a cohort study of patients with rheumatoid arthritis who newly started abatacept or TNF
inhibitors using claims data from Medicare and MarketScan. The primary outcome was a composite cardiovascular end point of
myocardial infarction (MI), stroke/transient ischemic attack, and coronary revascularization. To account for >60 baseline
characteristics, abatacept initiators were 1:1 propensity score (PS) matched to TNF initiators in each database. Cox proportional
hazards models estimated hazard ratio (HR) and 95% conﬁdence interval (CI) in the PS-matched cohort per database. A ﬁxed-
effects meta-analysis pooled database-speciﬁc HRs. We included a total of 13 039 PS-matched pairs of abatacept and TNF
inhibitor initiators (6103 pairs in Medicare and 6936 pairs in MarketScan). A total of 34.7% in Medicare and 19.8% in MarketScan
had baseline DM. The HR (95% CI) for the primary outcome associated with abatacept use versus TNF inhibitor was 0.81 (0.66–
0.99) in Medicare and 0.95 (0.74–1.23) in MarketScan, with a pooled HR of 0.86 (95% CI, 0.73–1.01; P=0.3 for heterogeneity). The
risk of the primary outcome was lower in abatacept initiators versus TNF inhibitors in the DM subgroup, with a pooled HR of 0.74
(95% CI, 0.57–0.96; P=0.7 for heterogeneity), but not in the non-DM subgroup, with a pooled HR of 0.94 (95% CI, 0.77–1.14; P=0.4
for heterogeneity).
Conclusions-—In this large population-based cohort of patients with rheumatoid arthritis, abatacept use appeared to be associated
with a modestly reduced cardiovascular risk when compared with TNF inhibitor use, particularly in patients with DM. ( J Am Heart
Assoc. 2018;7:e007393. DOI: 10.1161/JAHA.117.007393.)
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P atients with rheumatoid arthritis (RA) are at high risk ofdeveloping cardiovascular disease (CVD).1–9 The magni-
tude of cardiovascular risk in patients with RA is reported to
be at least comparable to that in diabetic patients, both
doubling the risk as compared with the general population.4
This increased risk in patients with RA is not fully explained by
baseline traditional CVD risk factors. Several studies report
that systemic inﬂammatory burden is a major independent
risk factor for CVD in patients with RA.5–9 Epidemiologic
studies report that the prevalence of insulin resistance is
associated with RA activity or severity.10–12 Biological
evidence further shows that the key inﬂammatory cytokines
in RA provide the link between inﬂammation and intermediary
metabolic outcomes, such insulin resistance or dyslipi-
demia.13 Consequently, patients with RA with sustained
disease activity are prone to develop metabolic syndrome,
which ultimately leads to premature atherosclerosis.8,10,11
Patients with RA with coexisting diabetes mellitus (DM),
therefore, would constitute a high cardiovascular risk subset
calling for particular attention.
Disease-modifying antirheumatic drugs (DMARDs) that
control systemic inﬂammation may reduce the cardiovascular
risk in patients with RA. In particular, the effect of biologic
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ORIGINAL RESEARCH
DMARDs on cardiovascular risk has been a clinically impor-
tant topic of interest on the basis of their potent anti-
inﬂammatory effect in RA. The use of tumor necrosis factor
(TNF) inhibitors is currently thought to be associated with a
reduced risk of CVD compared with use of nonbiologic
DMARD treatment in RA.14,15 Few studies have conducted a
head-to-head comparison of different biologic DMARDs. In a
recent cohort study of elderly patients with RA, use of
abatacept was associated with fewer coronary heart disease
events compared with use of TNF inhibitors.16 However, to
date, little is known with regard to comparative cardiovascular
safety of abatacept and TNF inhibitors in different patient
populations, such as younger or healthier populations, or in
high cardiovascular risk subsets, such as patients with RA
with underlying DM.
The objective of the present study was to compare
cardiovascular risk in patients with RA who were newly
initiated on abatacept versus TNF inhibitors in a population-
representative cohort using data from both public and
commercial insurance claims databases in the United States.
We also aimed to study the comparative cardiovascular safety
of these biologic agents in patients with RA stratiﬁed by the
presence of DM at baseline. Abatacept and TNF inhibitors are
interchangeably used to treat active RA,17,18 which strength-
ens study validity by minimizing confounding by indication
associated with disease duration or severity.
Methods
Data Sources
Using longitudinal data from 2 large US healthcare claims
databases (Medicare [Parts A/B/D 2008–2013] and Truven
“MarketScan” [January 2006–June 30, 2015]), we conducted
a cohort study of patients with RA who had been initiated on
either abatacept or TNF inhibitors. Medicare is a federally
funded health plan that provides healthcare coverage for
nearly all adults aged ≥65 years and some disabled patients
aged <65 years in the United States. Medicare Part A is
generally for inpatient care; Part B is for outpatient medical
services, including some drugs given in a physician’s ofﬁce or
clinic; and Part D is for outpatient prescription drug cover-
age.19 The MarketScan database contains longitudinal med-
ical and pharmacy claims from several different managed care
plans, representing a national commercially insured popula-
tion in the United States. The Institutional Review Board of the
Brigham and Women’s Hospital approved the study protocol
and privacy precautions. Because of the data use agreement
with the Centers for Medicare and Medicaid Services and with
Truven Health, the data, analytic methods, and study mate-
rials will not be made available to other researchers for
purposes of reproducing the results or replicating the
procedure.
Study Cohort
Eligible patients were those aged 18 years and older,
having at least 2 International Classiﬁcation of Diseases,
Ninth Revision (ICD-9) diagnosis codes of RA (code 714.x)
given on separate visits ≥7 days apart.20 Of these patients,
we identiﬁed new users of either abatacept or TNF
inhibitors (ie, adalimumab, certolizumab, etanercept, goli-
mumab, and inﬂiximab). The new users were deﬁned as
those who had no prior dispensing of abatacept or TNF
inhibitors for at least 12 months before the index date. The
index date was deﬁned as the date of ﬁrst dispensing
abatacept or a TNF inhibitor. Past or current use of
nonbiologic DMARDs was allowed, which included
methotrexate, hydroxychloroquine, leﬂunomide, azathioprine,
cyclophosphamide, cyclosporine, D-penicillamine, gold, and
sulfasalazine. Patients who used anakinra, rituximab,
tocilizumab, or tofacitinib in the 1 year before the index
period were excluded. Patients were allowed to contribute
multiple episodes to the study cohort as long as each
episode met the study enrollment criteria.
For the primary as-treated analysis, follow-up time started
the day after the index date and continued until the earliest
date among the following censoring events: discontinuation of
TNF inhibitors for those in the TNF inhibitor group (switching
to a different TNF inhibitor was allowed), discontinuation of
abatacept for those in the abatacept group, outcome
occurrence, insurance disenrollment, end of study database,
or death. Censoring attributable to discontinuation of the
study medication occurred at the last drug available date,
deﬁned as the last dispensing date plus days’ supply of a
given drug regardless of the gap between exhaustion of the
days’ supply of the previous dispensing and the next
dispensing. To estimate the drug adherence in the 2
treatment groups, we calculated proportions of days covered,
Clinical Perspective
What Is New?
• Despite comparable efﬁcacy to control rheumatoid arthritis,
use of abatacept was associated with a reduced cardiovas-
cular risk compared with use of tumor necrosis factor
inhibitors, particularly in diabetic patients.
What Are the Clinical Implications?
• Certain subsets of patients with rheumatoid arthritis with
underlying cardiovascular risk factors might beneﬁt from the
use of abatacept over tumor necrosis factor inhibitor with
regard to their cardiovascular risk.
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Table 1. Baseline Characteristics of Study Cohort Before PS Matching
Characteristics
DM Subgroup Non-DM Subgroup
Medicare MarketScan Medicare MarketScan
Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor
(n=2122) (n=9142) (n=1377) (n=11 057) (n=3985) (n=16 650) (n=5565) (n=54 407)
Demographics
Age, y 73.66.3 72.56.1 60.311.4 56.811.4 73.96.4 72.76.2 56.113.2 51.913.0
Female sex 80.4 77.6 80.1 71.7 84.5 79.3 82.6 75.8
Race
Black 9.9 11.6   4.8 6.4  
White 79.5 76.3   89.1 87.0  
Others 10.7 12.1   6.1 6.6  
RA medications
Hydroxychloroquine 27.2 22.2 22.4 23.1 29.1 24.3 21.2 24.1
Methotrexate 52.1 59.1 37.8 56.5 55.1 62.6 35.8 56.7
Leflunomide 19.5 15.5 14.7 13.0 20.4 15.9 13.6 11.6
Other DMARD 19.6 15.4 11.3 14.1 18.6 16.4 13.0 14.3
No. of DMARDs 1.20.9 1.10.8 0.90.9 1.10.8 1.20.8 1.20.8 0.80.9 1.10.8
Glucocorticoids
Inhaled glucocorticoids 24.9 27.0 20.0 20.9 21.5 22.0 14.1 17.2
Oral glucocorticoids
(≤30 d)
34.4 30.7 21.1 24.9 34.8 32.6 20.4 25.8
Oral glucocorticoid
(≤1 y)
71.9 68.5 53.2 62.2 74.0 71.7 49.1 62.4
Cumulative dose, mg* 12641468 11391522 11133564 11987597 11521316 11181356 9323550 112615 071
Analgesics
NSAIDs 40.3 45.5 33.1 47.8 37.2 41.5 31.2 48.0
Celecoxib 11.3 12.1 8.8 10.7 10.4 11.2 7.9 9.8
Opioids 39.0 36.5 24.8 28.3 32.3 30.0 19.3 21.7
Baseline CVD
Coronary heart disease 42.5 37.8 21.9 15.2 25.8 22.9 9.9 5.7
Stroke 9.1 8.3 3.9 3.2 6.2 5.8 2.4 1.3
PVD 22.3 20.4 7.0 5.1 13.0 11.1 3.0 1.7
Traditional CVD risk factors
Smoking 17.2 16.2 9.3 11.1 13.9 15.5 9.4 10.0
Hypertension 89.6 89.6 67.0 59.9 75.4 71.9 38.6 31.8
Hyperlipidemia 81.5 80.3 56.3 50.9 62.8 60.2 28.8 25.6
Obesity 31.3 31.9 19.6 17.9 16.4 15.4 9.2 7.8
Chronic kidney disease 22.0 18.0 9.9 6.6 10.79 8.7 3.4 1.9
DM complications
DM nephropathy 7.5 6.4 4.0 3.4    
DM neuropathy 19.8 19.4 14.2 9.5    
DM retinopathy 11.2 11.4 7.7 7.1    
Diabetic foot 10.4 8.0 4.8 3.3    
Continued
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Table 1. Continued
Characteristics
DM Subgroup Non-DM Subgroup
Medicare MarketScan Medicare MarketScan
Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor
(n=2122) (n=9142) (n=1377) (n=11 057) (n=3985) (n=16 650) (n=5565) (n=54 407)
Comorbidities
VTE 8.8 6.0 5.1 2.9 5.9 4.1 2.9 1.6
Atrial fibrillation 15.3 13.0 6.8 4.0 13.4 8.9 3.8 1.9
Heart failure 26.0 19.5 11.0 5.2 12.8 9.0 3.8 1.3
Asthma 17.0 16.8 15.3 11.2 12.5 11.7 9.0 7.6
COPD 26.7 26.9 11.8 9.2 20.6 20.5 7.9 5.2
Chronic liver disease 12.6 12.1 9.4 7.9 7.9 7.5 5.1 4.3
Hepatitis 1.9 2.2 1.1 1.2 1.1 1.6 0.9 1.1
Hypothyroidism 38.3 33.8 22.2 20.7 31.9 27.9 16.3 13.7
Depression 24.1 22.5 15.3 13.5 18.7 17.9 13.2 11.8
Fracture 15.1 12.9 9.3 6.9 13.9 11.4 6.5 4.5
Malignancy 18.1 14.9 11.1 7.3 16.3 14.5 8.8 5.2
Medications
Cardiovascular drugs
ACEIs/ARBs 61.6 62.8 41.2 49.7 43.5 41.7 19.3 20.5
b-Blockers 43.0 40.8 25.8 24.5 36.1 32.7 14.7 13.4
Calcium channel blockers 33.2 34.6 20.0 20.1 26.1 25.7 10.5 10.1
Nitrates 12.3 11.2 6.7 4.3 6.7 5.2 1.6 1.6
Antiarrhythmics 3.7 2.3 1.0 0.9 3.0 1.8 0.9 0.5
Anticoagulants 14.5 11.4 8.6 6.3 11.8 8.9 4.8 3.2
Antiplatelets 15.7 14.0 6.8 6.3 8.7 7.4 3.0 2.5
Statins 57.7 57.1 38.4 42.9 37.1 37.0 14.6 16.3
Other antilipid drugs 12.4 12.4 12.6 12.2 7.2 7.1 4.1 4.3
Loop diuretics 32.9 29.3 17.7 14.1 19.8 15.7 7.0 5.1
Thiazide 34.5 35.1 23.0 29.5 27.3 29.6 14.3 16.3
Other diuretics 11.3 9.6 7.9 7.8 8.7 8.0 5.0 4.7
DM medication
Insulin 28.6 29.0 26.8 32.5    
Metformin 31.6 37.0 30.1 41.2    
Sulfonylureas 21.0 24.1 16.6 18.1    
Thiazolidinediones 5.7 7.6 5.5 8.3    
DPP4 inhibitors 7.0 8.4 7.2 8.8    
Bronchodilators
Inhaled LABA 10.4 11.7 6.4 7.1 8.2 8.1 4.5 4.8
Inhaled SABA 17.3 18.6 15.0 15.3 12.9 13.8 9.8 11.0
Others
Benzodiazepines 5.9 6.1 19.9 22.1 6.6 5.4 16.1 17.8
Bisphosphonates 21.3 21.5 9.2 8.0 24.0 23.1 10.0 7.8
Continued
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deﬁned as the sum of days’ supply during follow-up time/the
follow-up time of a given patient.
Outcome Deﬁnition
The primary outcome of interest was a composite cardiovas-
cular end point of MI, coronary revascularization, and stroke/
transient ischemic attack (TIA). The date of composite
cardiovascular outcome was deﬁned by the ﬁrst occurrence
of any of the 3 components: MI, stroke/TIA, or coronary
revascularization. MI and stroke/TIA were identiﬁed using an
inpatient ICD-9 diagnosis code of MI (codes 410.x0 and
410.x1) in any position and stroke/TIA (codes 430, 431,
433.x1, 434.x1, 435, 436, and 362.3) in primary position.
Coronary revascularization was identiﬁed using ICD-9 proce-
dure codes, Current Procedural Terminology-5 codes, or
diagnosis-related group codes.
The secondary outcomes included each component of the
composite cardiovascular end point, heart failure (HF), and
venous thromboembolism (VTE), consisting of deep venous
thrombosis and pulmonary embolism. Any inpatient ICD-9
diagnosis code (code 428.xx) was used to identify HF. To
identify VTE, we used any inpatient ICD-9 diagnosis code for
deep vein thrombosis (code 451.1x) or pulmonary embolism
(code 415.1x) combined with at least 1 outpatient pharmacy
claims for anticoagulants. In prior studies, the positive
predictive values of these algorithms to identify each CVD
outcome were at least 80%.21–25
Baseline Covariates
We assessed variables potentially associated with RA severity
and risk of CVD, HF, or VTE, on the basis of the data from the
12-month period before the index date. These variables were
cohort entry year, demographics, traditional risk factors for
CVD (ie, hypertension, dyslipidemia, chronic kidney disease,
peripheral vascular disease, smoking, and obesity), comor-
bidities, RA-related medications (eg, DMARDs, NSAIDs, and
Table 1. Continued
Characteristics
DM Subgroup Non-DM Subgroup
Medicare MarketScan Medicare MarketScan
Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor
(n=2122) (n=9142) (n=1377) (n=11 057) (n=3985) (n=16 650) (n=5565) (n=54 407)
PPIs 52.6 51.2 33.3 35.9 43.1 41.6 24.5 25.8
H1 blocker 15.7 16.3 17.4 20.7 11.8 12.1 12.9 16.7
H2 blocker 7.5 10.3 3.0 4.9 6.9 7.2 3.2 3.2
No. of unique generics 17.77.3 17.47.7 13.910.7 15.58.6 13.26.0 12.66.2 9.08.4 10.37.0
Healthcare use during preindex period
Tests ever ordered
Hemoglobin A1C 58.9 59.5 57.6 62.2 8.0 7.4 8.8 9.1
ESR 71.1 64.8 63.3 69.7 67.0 61.8 65.4 71.4
C-reactive protein 61.3 55.8 53.2 61.0 56.9 52.9 56.5 62.7
Serum creatinine 25.5 22.5 25.1 27.0 27.4 24.2 25.8 26.7
Lipid/cholesterol panel 59.1 58.8 52.9 59.7 44.5 42.2 35.4 38.5
ECG 63.7 59.3 50.5 43.3 51.3 47.2 35.3 29.0
Echocardiogram 37.3 33.0 26.1 19.2 27.3 23.2 16.3 10.6
Pulmonary function test 21.1 19.8 22.7 17.7 17.1 14.8 15.9 12.2
No. of physician visits 19.810.7 18.210.5 17.510.2 15.28.7 16.39.4 14.89.0 13.28.3 11.57.3
No. of ED visits 1.54.6 1.22.8 1.12.1 0.82.0 0.81.5 0.82.0 0.61.4 0.51.4
Any hospitalization 37.2 32.2 26.1 20.3 26.2 22.6 16.7 12.3
Recent hospitalization 2.0 2.7 1.2 1.6 1.3 1.5 0.8 0.8
Variables showing the frequency of <5% are not shown: alcohol, GLP, glucagon-like peptide; 1 receptor agonists, a-glucosidase inhibitors, theophylline, and inhaled anticholinergics.
Continuous variables are presented as meanSD, and binary variables are presented as percentages. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DM, diabetes mellitus; DMARD, disease-modifying antirheumatic drug; DPP4, dipeptidyl peptidase 4;
ED, emergency department; ESR, erythrocyte sediment rate; GLP, glucagon-like peptide; LABA, long-acting b2 agonist; PPI, proton pump inhibitor; PS, propensity score; PVD, peripheral
vascular disease; RA, rheumatoid arthritis; SABA, short-acting b2 agonist; TNF, tumor necrosis factor; and VTE, venous thromboembolism.
*Cumulative dose during the 365 days before the index date was calculated by summing up the prednisone equivalent doses of glucocorticoid compounds used.
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steroids), other medications, markers of healthcare use
intensity, and the use of laboratory or other diagnostic tests
(Table 1). Existing CVD conditions (including coronary heart
disease encompassing acute and old MI, acute coronary
syndrome, stable angina, and other chronic ischemic heart
disease and stroke/TIA), HF, and VTE were also included as
baseline covariates. To further assess potential differences in
comorbidities between the 2 treatment groups, we used a
Charlson and Deyo comorbidity score on the basis of 17
comorbidity categories.26
Statistical Analysis
For each database, we compared baseline characteristics of
the abatacept and TNF inhibitor groups. PS matching was
used to control for >60 potential confounders between the 2
groups. To estimate the PS, we used multivariable logistic
regression analysis that included all of baseline variables
listed in Table 1 plus the index year. Because of the
anticipated differences between the Medicare and
commercial insurance populations, we estimated the PS per
database and performed nearest neighbor matching at 1:1
ratio using a caliper of 0.025 on the PS scale within each
subgroup (DM and non-DM subgroups) per database. The DM
and non-DM subgroups were then merged together to create
the main PS-matched cohort in each database (Figure 1). The
achieved PS balance within each database was inspected by
tabulating baseline patient characteristics by treatment status
and by examining the standardized differences.
After PS matching, incidence rates of primary and
secondary outcomes were calculated in the main cohort and
in the subgroups with or without DM in each database. Cox
proportional hazards models estimated the database-speciﬁc
hazard ratio (HR) with 95% conﬁdence interval (CI) for the
primary and secondary outcomes associated with initiation of
abatacept versus TNF inhibitors. We tested the proportional
hazards assumption using the interaction term between
exposure and follow-up time, and the assumption was not
violated in any of the models.27 Kaplan-Meier plots were also
used to inspect proportionality of hazards, and the follow-up
Figure 1. Study cohort selection process. In each of the 2 databases, the propensity score (PS) matching was done in the diabetes mellitus
(DM) and non-DM subgroups separately ﬁrst, and the 2 subgroups were merged to create the main PS-matched cohort. RA indicates rheumatoid
arthritis; and TNF, tumor necrosis factor.
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Table 2. Baseline Characteristics of 1:1 PS-Matched Cohorts
Characteristics
DM Subgroup Non-DM Subgroup
Medicare MarketScan Medicare MarketScan
Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor
(n=2119) (n=2119) (n=1371) (n=1371) (n=3984) (n=3984) (n=5565) (n=5565)
Demographics
Age, y 73.56.3 73.46.3 60.211.4 60.011.8 73.96.4 73.96.5 56.113.2 56.113.6
Female sex 80.4 79.9 80.0 79.1 84.5 84.4 82.6 81.9
Race
Black 9.9 10.4   4.8 4.9  
White 79.5 79.0   89.1 88.7  
Others 10.7 10.6   6.1 6.4  
Nonbiological DMARDs
Hydroxychloroquine 27.2 21.7 22.5 19.8 29.1 24.5 21.2 20.5
Methotrexate 52.2 58.6 37.9 50.0 55.2 61.0 35.8 49.0
Leflunomide 19.4 15.6 14.7 12.8 20.4 17.1 13.6 10.9
Other DMARDs 19.6 14.4 11.4 11.5 18.6 16.9 13.0 12.4
No. of DMARDs 1.20.9 1.10.8 0.90.8 0.90.9 1.20.8 1.20.8 0.90.9 0.80.9
Glucocorticoids
Inhaled glucocorticoids 24.9 27.8 20.1 17.9 21.5 23.2 14.1 16.0
Oral glucocorticoids
(≤30 d)
34.4 30.2 21.2 20.6 34.8 32.6 20.4 22.5
Oral glucocorticoids
(≤1 y)
71.9 68.9 53.5 53.8 74.0 73.4 49.1 53.8
Cumulative dose, mg* 12641469 11561529 11183571 9202077 11511315 11681431 9323550 9473298
Analgesics
NSAIDs 40.4 41.1 33.3 32.1 37.2 36.7 31.2 30.4
Celecoxib 11.3 10.5 8.8 9.3 10.4 10.7 7.9 7.4
Opioids 39.0 38.6 25.0 24.9 32.3 31.9 19.3 17.9
Baseline CVD
Coronary heart disease 42.4 43.6 21.6 21.3 25.8 25.9 9.9 10.6
Stroke 9.0 8.6 3.7 3.7 6.2 6.7 2.4 2.7
PVD 22.3 21.4 6.9 6.4 12.9 12.5 3.0 3.3
Traditional CVD risk factors
Smoking 17.1 17.4 9.3 9.3 13.9 14.5 9.4 9.0
Hypertension 89.6 90.7 66.8 66.0 75.4 75.4 38.6 38.5
Hyperlipidemia 81.5 81.6 56.1 54.3 62.8 62.9 28.8 28.3
Obesity 31.3 34.4 19.5 18.4 16.4 15.6 9.2 8.9
Chronic kidney disease 21.9 22.8 9.7 10.5 10.8 10.0 3.4 3.5
DM complications
DM nephropathy 7.5 7.5 4.0 3.9    
DM neuropathy 19.9 18.3 13.9 15.0    
DM retinopathy 11.2 11.0 7.7 7.6    
Diabetic foot 10.0 10.2 4.8 4.8    
Continued
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Table 2. Continued
Characteristics
DM Subgroup Non-DM Subgroup
Medicare MarketScan Medicare MarketScan
Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor
(n=2119) (n=2119) (n=1371) (n=1371) (n=3984) (n=3984) (n=5565) (n=5565)
Comorbidities
VTE 8.7 8.8 5.0 5.3 5.9 6.2 2.9 2.9
Atrial fibrillation 15.2 14.4 6.7 7.1 13.4 13.1 3.8 3.7
Heart failure 25.9 25.6 10.7 11.2 12.8 12.4 3.8 3.8
Asthma 16.9 19.5 15.1 14.2 12.5 11.8 9.0 9.3
COPD 26.7 30.3 11.7 13.8 20.6 21.8 7.9 7.7
Chronic liver disease 12.6 12.8 9.4 8.8 7.9 8.0 5.1 4.8
Hypothyroidism 38.3 36.7 22.3 23.0 31.9 29.5 16.3 15.3
Depression 24.0 23.5 15.3 14.7 18.7 19.2 13.2 11.8
Fracture 15.1 15.4 9.3 8.2 13.9 12.3 6.5 6.2
Malignancy 18.1 17.0 11.1 9.8 16.3 16.8 8.8 9.2
Medications
Cardiovascular drugs
ACEIs/ARBs 61.6 62.2 41.4 39.8 43.5 43.2 19.3 18.9
b-Blockers 43.0 42.5 25.8 26.2 36.1 36.6 14.7 15.2
Calcium channel blockers 33.1 33.7 20.1 20.4 26.1 25.8 10.5 10.6
Nitrates 12.3 13.3 6.6 6.7 6.7 6.7 1.6 1.8
Antiarrhythmics 3.6 3.8 1.0 1.1 3.0 3.3 0.9 1.0
Anticoagulants 14.4 15.1 8.5 9.1 11.8 11.9 4.8 5.0
Antiplatelets 15.6 16.5 6.8 6.1 8.7 9.1 3.0 3.3
Statins 57.6 58.2 38.5 38.2 37.1 37.6 14.6 15.4
Other antilipid drugs 12.4 12.7 12.6 13.2 7.2 6.9 4.1 4.1
Loop diuretics 32.8 32.6 17.7 18.2 19.8 18.7 7.0 7.6
Thiazide 34.5 33.9 23.1 21.9 27.3 26.7 14.3 14.5
Other diuretics 11.3 11.0 8.0 6.3 8.7 8.6 5.0 5.1
DM medication
Insulin 28.7 27.8 26.8 26.7    
Metformin 31.6 30.3 30.3 31.5    
Sulfonylureas 21.0 20.2 16.6 17.7    
Thiazolidinediones 5.7 5.0 5.5 6.0    
DPP4 inhibitors 7.0 7.4 7.2 7.1    
Bronchodilators
Inhaled LABA 10.4 12.3 6.4 6.6 8.2 8.8 4.5 5.1
Inhaled SABA 17.3 17.8 15.1 14.5 12.9 14.1 9.8 9.8
Others
Benzodiazepines 6.0 5.4 19.9 20.5 6.6 6.7 16.1 16.7
Bisphosphonates 21.2 20.9 9.2 8.7 24.0 24.1 10.0 10.6
PPIs 52.6 52.5 33.4 31.5 43.1 43.4 24.5 24.9
Continued
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time between treatment groups was compared in each
database. HRs from the 2 databases were then pooled by
an inverse variance–weighted ﬁxed-effects model. All analy-
ses were completed using SAS 9.4 (SAS Institute) software.
Results
Cohort Selection and Patient Characteristics
Figure 1 illustrates the study cohort selection process. After
applying the inclusion and exclusion criteria, we identiﬁed a
total of 104 305 patients with RA who had been newly initiated
on either abatacept or TNF inhibitors from the 2 databases.
Approximately 35% of Medicare and 17% of MarketScan
enrollees had DM at baseline. Before PS matching, the
Medicare cohort showed higher rates for most comorbidities
associated with high cardiovascular risk compared with the
MarketScan cohort in both subgroups. Similarly, DM subgroups
showed higher rates for these comorbidities than non-DM
subgroups in both databases (Table 1).
After 1:1 PS matching, we identiﬁed a total of 13 039 pairs
of abatacept and TNF inhibitor initiators from the 2 databases
(6103 pairs in Medicare and 6936 pairs in MarketScan). Of
those pairs, 2119 (34.7%) in Medicare and 1371 (19.8%) in
MarketScan were identiﬁed as the DM subgroup, whereas
3984 (65.3%) from Medicare and 5565 (80.2%) from MarketS-
can were included in the non-DM subgroup. All baseline
covariates, including cardiovascular risk factors (eg, hyperten-
sion, hyperlipidemia, and previous cardiovascular events), were
well balanced in the PSmatched cohorts, with the standardized
difference of covariate prevalence <0.1 (Table 2). During the
follow-up, mean proportions of days covered were signiﬁcantly
higher in abatacept users than TNF inhibitor users in the
PS-matched cohorts across the 2 databases (Table 3).
Cardiovascular Risk Associated With the Use of
Abatacept
During the total of 31 733 person-years of follow-up in the
PS-matched cohorts from the 2 databases, 299 abatacept
Table 2. Continued
Characteristics
DM Subgroup Non-DM Subgroup
Medicare MarketScan Medicare MarketScan
Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor
(n=2119) (n=2119) (n=1371) (n=1371) (n=3984) (n=3984) (n=5565) (n=5565)
H1 blocker 15.7 15.6 17.4 18.5 11.9 10.9 12.9 13.2
H2 blocker 7.5 8.4 3.0 3.2 6.9 7.3 3.2 3.5
No. of unique generics 17.77.3 17.67.5 13.910.7 13.89.5 13.26.0 13.26.4 9.08.4 9.17.3
Healthcare use
Tests ever ordered
Hemoglobin A1C 58.9 59.4 57.6 57.2 8.0 7.6 8.8 8.8
ESR 71.1 67.6 63.4 64.4 67.0 64.9 65.4 65.2
C-reactive protein 61.2 61.2 53.4 54.2 56.9 57.2 56.5 56.4
Serum creatinine 25.5 24.7 25.2 24.0 27.4 27.4 25.8 25.3
Lipid/cholesterol panel 59.1 59.7 53.1 52.4 44.6 45.1 35.4 34.3
ECG ever ordered 63.6 64.2 50.3 48.7 51.3 51.1 35.3 35.3
Echocardiogram 37.3 37.9 25.9 25.6 27.2 26.3 16.3 16.5
Pulmonary function test 21.1 21.1 22.5 21.1 17.0 15.7 15.9 15.0
No. of physician visits 19.810.6 19.911.3 17.410.0 17.611.2 16.39.3 16.39.8 13.28.3 13.18.9
No. of ED visits 1.54.6 1.42.8 1.02.1 1.12.3 0.81.5 0.81.8 0.61.4 0.61.6
Any hospitalization 37.1 37.6 25.8 27.1 26.2 26.5 16.7 16.4
Recent hospitalization 2.0 2.0 1.2 1.8 1.3 1.5 0.8 1.0
Variables showing the frequency of <5% are not shown: alcohol, GLP, glucagon-like peptide; 1 receptor agonists, a-glucosidase inhibitors, theophylline, and inhaled anticholinergics.
Continuous variables are presented as meanSD, and binary variables are presented as percentages. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DM, diabetes mellitus; DMARD, disease-modifying antirheumatic drug; DPP4, dipeptidyl peptidase 4;
ED, emergency department; ESR, erythrocyte sediment rate; GLP, glucagon-like peptide; LABA, long-acting b2 agonist; PPI, proton pump inhibitor; PS, propensity score; PVD, peripheral
vascular disease; SABA, short-acting b2 agonist; TNF, tumor necrosis factor; and VTE, venous thromboembolism.
*Cumulative dose during the 365 days before the index date was calculated by summing up the prednisone equivalent doses of glucocorticoid compounds used.
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initiators and 333 TNF inhibitor initiators had the composite
cardiovascular events. The incidence rate of the composite
cardiovascular outcome was 2.38 per 100 person-years for
abatacept initiators and 2.97 per 100 person-years for TNF
inhibitors in Medicare. In MarketScan, the incidence rate of
the composite cardiovascular outcome was 1.38 per
100 person-years for abatacept initiators and 1.45 per
100 person-years for TNF inhibitor initiators (Table 4). The
risk of the composite cardiovascular outcome was lower in
abatacept initiators versus TNF inhibitor in Medicare, with
the HR (95% CI) of 0.81 (0.66–0.99), but not in MarketS-
can, with the HR (95% CI) of 0.95 (0.74–1.23). When
pooling the 2 database-speciﬁc HRs, the risk of the
composite cardiovascular events in abatacept initiators
was numerically, not statistically signiﬁcantly, lower com-
pared with TNF inhibitors, with the pooled HR (95% CI) of
0.86 (0.73–1.01; P=0.34 for heterogeneity). Similarly,
composite cardiovascular event-free survival curves
diverged from the beginning of follow-up (Figure 2A) in
the Medicare database, whereas there was no curve
separation between the 2 treatments in the MarketScan
database (Figure 2B).
Subgroup Analysis by Baseline DM
In the subgroup with DM (Table 4), the HR (95% CI) for
composite cardiovascular end point comparing abatacept
versus TNF inhibitor initiators was 0.72 (0.53–0.99) in
Medicare and 0.79 (0.50–1.25) in MarketScan, with a pooled
HR (95% CI) of 0.74 (0.57–0.96; P=0.7 for heterogeneity). In
the subgroup without DM (Table 4), the HR (95% CI) was 0.88
(0.67–1.14) in Medicare and 1.03 (0.76–1.40) in MarketScan,
with a pooled HR (95% CI) of 0.94 (0.77–1.14; P=0.4 for
heterogeneity).
Table 4. Incidence Rates and HRs of Composite Cardiovascular End Point in Abatacept Initiators Versus TNF Inhibitor Initiators:
PS-Matched Analysis
Subgroup Database
After PS Matching
Events Incidence Rate* HR (95% CI) Pooled HR (95% CI)
Main cohort Medicare 185 2.38 0.81 (0.66–0.99) 0.86 (0.73–1.01)
205 2.97 1 
MarketScan 114 1.38 0.95 (0.74–1.23) 
128 1.45 1 
DM subgroup Medicare 71 2.85 0.72 (0.53–0.99) 0.74 (0.57–0.96)
90 3.95 1 
MarketScan 35 2.24 0.79 (0.50–1.25) 
44 2.85 1 
Non-DM subgroup Medicare 114 2.16 0.88 (0.67–1.14) 0.94 (0.77–1.15)
115 2.49 1 
MarketScan 79 1.18 1.03 (0.76–1.40) 
84 1.15 1 
CI indicates conﬁdence interval; DM, diabetes mellitus; HR, hazard ratio; PS, propensity score; and TNF, tumor necrosis factor.
*Per 100 person-years.
Table 3. Follow-Up Times and PDCs of PS-Matched Cohorts by Baseline DM Status and Database
Variable
DM Subgroup Non-DM Subgroup
Medicare MarketScan Medicare MarketScan
Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor Abatacept TNF Inhibitor
(n=2119) (n=2119) (n=1371) (n=1371) (n=3984) (n=3984) (n=5565) (n=5565)
Follow-up time, d 423409 393409 415488 412487 483456 424432 438501 478540
PDC* 0.730.26 0.580.32 0.660.29 0.480.32 0.780.22 0.620.33 0.650.30 0.460.32
Data are given as meanSD. DM indicates diabetes mellitus; PDC, proportion of days covered; PS, propensity score; and TNF, tumor necrosis factor.
*Each comparison of mean PDCs between abatacept and TNF inhibitor users was statistically signiﬁcant.
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Stratiﬁed Analysis by DM and Age
To further delineate the age and DM effect on the cardiovas-
cular risk associated with abatacept versus TNF inhibitors, we
stratiﬁed patients in MarketScan by their age (Table 5) (the
old [≥65 years] and the young [<65 years]) and their baseline
DM status. The old/DM subset showed the highest incidence
rate of CVD events, and the PS-matched HR (95% CI) was 0.74
(0.39–1.40). In the young/DM subset, the HR (95% CI) was
1.42 (0.70–2.86). In the non-DM subgroup, the HR (95% CI)
was 1.09 (0.71–1.67) in the old and 1.02 (0.65–1.61) in the
young.
We also performed a Cox regression analysis in the main
cohort of each database to test interaction between abata-
cept treatment and the presence of DM but did not ﬁnd any
statistically signiﬁcant interaction (P>0.05 for the interaction
term) in either database.
Secondary Analysis
Our secondary analyses showed similar ﬁndings. There was an
association between a lower risk for MI (pooled HR [95% CI]
=0.77 [0.59–1.00]; P=0.3 for heterogeneity) and coronary
revascularization (pooled HR [95% CI]=0.74 [0.57–0.97];
P=1.0 for heterogeneity) among abatacept initiators com-
pared with TNF inhibitors in the main cohort (Figure 3A). The
risk for the other secondary outcomes (stroke/TIA, HF, and
VTE) was not different between the 2 groups in the main
cohort and DM and non-DM subgroups (Figure 3A through
3C). However, there was a trend toward an increased risk for
Table 5. Incidence Rates and HRs of Composite Cardiovascular End Point in Abatacept Initiators Versus TNF Inhibitor Initiators in
Elderly and Younger Age Groups in the MarketScan Database
Subgroup Database
After PS Matching
Exposure Events Incidence Rate* HR (95% CI)
DM subgroup ≥65 y (n=439 for each group) Abatacept 16 3.18 0.74 (0.39–1.40)
TNF inhibitor 22 4.31 1
<65 y (n=930 for each group) Abatacept 19 1.80 1.42 (0.70–2.86)
TNF inhibitor 14 1.30 1
Non-DM subgroup ≥65 y (n=1295 for each group) Abatacept 42 2.71 1.09 (0.71–1.67)
TNF inhibitor 44 2.47 1
<65 y (n=4267 for each group) Abatacept 36 0.70 1.02 (0.65–1.61)
TNF inhibitor 39 0.68 1
CI indicates conﬁdence interval; DM, diabetes mellitus; HR, hazard ratio; PS, propensity score; and TNF, tumor necrosis factor.
*Per 100 person-years.
Figure 2. Composite cardiovascular disease (CVD) event-free survival curve in the main propensity
score–matched cohort of the 2 data sources (Medicare [A] and MarketScan [B]). TNF indicates tumor
necrosis factor.
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VTE associated with abatacept versus TNF inhibitors in the
MarketScan cohort.
Discussion
In this large cohort study pooling data from 2 large national
public and commercial health plans in the United States,
abatacept use appears to be associated with a modestly
reduced risk of composite cardiovascular event, albeit statis-
tically not signiﬁcant compared with TNF inhibitor use. There
was a decreased risk for MI and coronary revascularization in
abatacept initiators versus TNF inhibitors. For other sec-
ondary end points, including stroke/TIA, HF, and VTE, the risk
was similar between the 2 groups. In the stratiﬁed analysis by
DM, we found that the risk of composite cardiovascular end
point was 26% lower with abatacept than TNF inhibitors
among the high cardiovascular risk subset (ie, the DM
subgroup). However, in the non-DM subgroup, the risk of
composite cardiovascular event was similar between the 2
drug groups.
When we looked at each database separately, the DM
subgroup from the Medicare database showed a signiﬁcant
association between the use of abatacept and a reduced
cardiovascular risk, whereas the non-DM subgroup showed
only such a trend. In the MarketScan database, we noted a
trend toward an association between the use of abatacept
and decreased cardiovascular risk only in the DM subgroup.
Because the MarketScan cohort generally consists of younger
and healthier patients than those in Medicare (Tables 1 and
2), it is possible that a certain subset of patients with RA (eg,
with DM and/or age ≥65 years) would potentially beneﬁt
from the use of abatacept over TNF inhibitors with regard to
their cardiovascular risk. To further assess whether older age
and DM status affects the cardiovascular risk differently
related to use of abatacept versus TNF inhibitors, we stratiﬁed
our MarketScan cohort by DM status and age (≥65 and
<65 years). In this analysis, we observed a trend toward a
decreased cardiovascular risk only in the highest cardiovas-
cular risk subset (age ≥65 years and with DM), but we did not
ﬁnd such a trend in the other subsets. In addition, in either
data set, we found no signiﬁcant interaction between
abatacept treatment and the presence of DM on cardiovas-
cular risk. Therefore, although our ﬁndings may suggest that
beneﬁt associated with abatacept use compared with TNF
inhibitors could be greater in those with higher underlying
cardiovascular risk, caution is needed in interpreting our
results. Furthermore, future research should follow to conﬁrm
this hypothesis.
Figure 3. Comparative risk of secondary cardiovascular outcomes between abatacept vs tumor necrosis factor (TNF) inhibitor initiators. A, The
main propensity score (PS)–matched cohort, which combines subgroups with diabetes mellitus (DM; B) and without DM (C). CI indicates
conﬁdence interval; HR, hazard ratio; and TIA, transient ischemic attack.
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Because abatacept and TNF inhibitors have comparable
anti-inﬂammatory efﬁcacy, observed in several randomized
trials,28–32 it is unlikely that the potential cardiovascular
beneﬁts seen in the abatacept group are attributable to better
control of RA activity. Abatacept has been reported to improve
insulin sensitivity and restore lipid proﬁle in patients with
RA.33,34 These favorable metabolic effects of abatacept may
explain our ﬁndings of reduced risks of CVD in patients with RA
with underlying DM. Furthermore, it is possible that the
costimulation blockade affecting diverse downstream anti-
inﬂammatory pathways beyond cytokine-mediated pathways, a
unique mechanism of action of abatacept, could have provided
a beneﬁcial cardiovascular effect among those at high risk of
accelerated atherosclerosis, such as patients with DM or
elderly patients. In previous experimental studies, the critical
roles of local CD4 T cells and regulatory T cells have been
shown in animal models of atherosclerosis,35–37 with their
functions being dependent on costimulation by interaction
between B7 and CD28 or cytotoxic T-lymphocyte-associated
protein 4 (CTLA4).38–41 Abatacept use has also been shown to
beneﬁt the progression of atherosclerosis in animal mod-
els.39,40 Because both RA and DM are important risk factors for
atherosclerotic CVD,6,12 our study will help guide treatment
decision making in routine rheumatology practice.
In addition to atherosclerotic CVD, we have assessed other
cardiovascular outcomes in the secondary analysis. We did
not see a signiﬁcant difference in the HF risk between
abatacept and TNF inhibitor initiators regardless of baseline
DM. To date, no apparently increased or decreased risk of HF
with use of TNF inhibitors in the RA population has been
reported.42,43 With regard to the risk of VTE, overall, there was
no signiﬁcant difference between abatacept and TNF
inhibitors. However, the VTE risk was numerically higher in
abatacept initiators versus TNF inhibitors in both patients with
DM and without DM in MarketScan. Because of the low event
rate of the VTE outcome, our results may highlight the need
for future research on this topic.
Other strengths of this study include use of rigorous
pharmacoepidemiologic methods, including the new-user
design with active comparators.44 Both abatacept and TNF
inhibitors are shown to be effective in treating active RA in
clinical trials,28–32 and they are recommended equivalently by
the current international guidelines against refractory RA in
patients in whom nonbiological DMARD treatment has failed
or in those who have poor prognostic factors.17,18 Because
the clinical circumstances for them to be used in patients with
RA are similar, we expect that confounding by indication or
bias by disease severity to be minimal. In support of the
effectiveness by active comparator design in achieving
comparability between comparison groups, all the baseline
covariates were well balanced, even before PS matching
(Table 1). In particular, RA severity–related covariates, such
as nonbiological DMARD and glucocorticoid use, traditional
CVD risk factors, and cardiovascular drug use were similar
between the 2 groups, even before PS matching. Because TNF
inhibitors were available earlier than abatacept, we accounted
for the calendar year of the index date. Furthermore, to
control for potential difference in their RA duration between
the 2 groups, we excluded all patients who had ever
dispensed any biological DMARD during 1 year before the
index date and included the number of DMARDs that they had
used in the PS model. In addition, we also performed
extensive covariate adjustment using 1:1 PS matching for
each database. By examining 2 large data sets with different
population characteristics and including a subgroup of
patients at high risk for CVD, our results provide generalizable
and clinically important real-world based evidence on the
comparative cardiovascular safety of biologics. Last, we
performed several prespeciﬁed secondary and subgroup
analyses that showed consistent ﬁndings.
There are also limitations in this study. First, as inherent in
any observational studies, our study is subject to residual or
unmeasured confounding. In particular, we did not have
information on RA activity and duration, physical activity,
family history of CVD, diet pattern, or body mass index.
However, we tried to minimize such unmeasured confounding
by use of the aforementioned new user and active comparator
design44 and PS matching methods. Second, even though our
cohort size is large, it may be possible that we did not have an
adequate statistical power for subgroup or sensitivity analysis.
Third, this study may be subject to residual confounding,
surveillance bias, and misclassiﬁcation bias. We tried to
minimize residual confounding and surveillance bias by PS
matching against as many relevant covariates as possible,
including healthcare use frequencies (Table 2). We also used
previously validated claims-based algorithms to deﬁne CVD
outcomes.21–25 Last, mean proportions of days covered
during follow-up times were different between the 2 treatment
groups, suggesting a better drug adherence in abatacept
users. However, whether such differences in medication
adherence would result in a clinically signiﬁcant difference in
RA activity control or CVD risk is unknown.
In conclusion, we found that in patients with RA with DM,
those initiating abatacept may have a reduced risk of
cardiovascular outcomes compared with those initiating TNF
inhibitors. There was a trend that this beneﬁt was greater in
Medicare enrollees than MarketScan enrollees. This ﬁnding is
in line with previous knowledge on the metabolic effects of
abatacept in patients with RA and its protective effect in
animal models of atherosclerosis. However, despite our
rigorous study design and methods, including PS matching,
there may be unmeasured confounding that accounts for the
differential ﬁndings between 2 databases. Furthermore, future
research should examine a potential cardioprotective
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mechanism of abatacept not shared by TNF inhibitor therapy
in an RA subset at high cardiovascular risk.
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